Free Trial

DexCom (DXCM) Stock Forecast & Price Target

DexCom logo
$81.62 +11.36 (+16.17%)
Closing price 04:00 PM Eastern
Extended Trading
$81.24 -0.38 (-0.46%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
16

Based on 20 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 4 have given a hold rating, 13 have given a buy rating, and 3 have given a strong buy rating for DXCM.

Consensus Price Target

$99.22
21.57% Upside
According to the 20 analysts' twelve-month price targets for DexCom, the average price target is $99.22. The highest price target for DXCM is $120.00, while the lowest price target for DXCM is $82.00. The average price target represents a forecasted upside of 21.57% from the current price of $81.62.
Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

Sign Up

DXCM Analyst Ratings Over Time

TypeCurrent Forecast
5/2/24 to 5/2/25
1 Month Ago
4/2/24 to 4/2/25
3 Months Ago
2/2/24 to 2/1/25
1 Year Ago
5/3/23 to 5/2/24
Strong Buy
3 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$99.22$99.82$99.29$141.67
Forecasted Upside21.57% Upside46.50% Upside14.35% Upside11.86% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DexCom Stock vs. The Competition

TypeDexComMedical CompaniesS&P 500
Consensus Rating Score
2.95
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside22.65% Upside3,310.23% Upside18.54% Upside
News Sentiment Rating
Positive News

See Recent DXCM News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/2/2025Piper Sandler
2 of 5 stars
Matt O'Brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$100.00 ➝ $90.00+10.16%
5/2/2025Canaccord Genuity Group
2 of 5 stars
William Plovanic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$103.00 ➝ $106.00+29.66%
5/2/2025Robert W. Baird
2 of 5 stars
Jeff Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$115.00 ➝ $105.00+49.44%
4/10/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$85.00+27.17%
3/21/2025Cfra Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Perez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/8/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$101.00 ➝ $104.00+25.40%
2/14/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Wood
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$75.00 ➝ $82.00-2.49%
2/3/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Issie Kirby
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$85.00 ➝ $115.00+32.44%
1/16/2025Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/25/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$82.00 ➝ $86.00+16.55%
10/25/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$120.00 ➝ $115.00+53.54%
10/25/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetStrong-Buy ➝ Strong-Buy$115.00 ➝ $99.00+32.18%
10/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$115.00 ➝ $105.00+39.55%
10/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$75.00 ➝ $85.00+15.66%
10/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$90.00 ➝ $87.00+19.10%
8/23/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $100.00+38.35%
7/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$138.00 ➝ $113.00+67.33%
7/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$156.00 ➝ $120.00+88.62%
7/26/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$163.00 ➝ $95.00+49.42%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:22 PM ET.


Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 23, 2025. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • The current stock price is around $68.85, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $139.24.
  • DexCom, Inc. has shown strong institutional support, with 97.75% of its stock owned by institutional investors and hedge funds, indicating confidence in the company's future performance.
  • The company reported a return on equity of 30.14%, suggesting efficient management and profitability, which can be attractive to investors seeking growth.
  • Recent upgrades from analysts, including a consensus target price of $99.00, reflect positive sentiment and potential for stock appreciation.
  • DexCom, Inc. focuses on continuous glucose monitoring systems, a growing market due to increasing diabetes prevalence, positioning the company for future growth.

DexCom
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • The company recently missed earnings expectations, reporting $0.45 EPS compared to the consensus estimate of $0.50, which may raise concerns about its short-term financial performance.
  • Insider selling has occurred, with corporate insiders selling a total of 105,009 shares worth over $8 million in the last three months, which could signal a lack of confidence in the stock's near-term prospects.
  • The stock has experienced significant volatility, with a beta of 1.50, indicating that it may be more volatile than the overall market, which could be a risk for conservative investors.
  • Despite strong institutional ownership, the company has a relatively high price-to-earnings ratio of 48.15, suggesting that the stock may be overvalued compared to its earnings.
  • With a debt-to-equity ratio of 0.59, while manageable, it indicates that the company is using some leverage, which could pose risks if market conditions change.

DXCM Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $99.22, with a high forecast of $120.00 and a low forecast of $82.00.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings, 13 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DXCM shares.

According to analysts, DexCom's stock has a predicted upside of 21.57% based on their 12-month stock forecasts.

Over the previous 90 days, DexCom's stock had 3 upgrades by analysts.

DexCom has been rated by research analysts at Canaccord Genuity Group, Cfra Research, Citigroup, Mizuho, Morgan Stanley, Piper Sandler, Redburn Atlantic, Robert W. Baird, and Wells Fargo & Company in the past 90 days.

Analysts like DexCom more than other "medical" companies. The consensus rating score for DexCom is 2.95 while the average consensus rating score for "medical" companies is 2.81. Learn more on how DXCM compares to other companies.


This page (NASDAQ:DXCM) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners